Safety, Tolerability, and Efficacy of Azilsartan Medoxomil With or Without Chlorthalidone During and After 8 Months of Treatment for Hypertension

Autor:	Alison Handley, Bruce Barger, Mark S. Kipnes, Eric E. Lloyd, Andrew V. Roberts
Jazyk:	angličtina
Rok vydání:	2015
Předmět:	Adult Male medicine.medical_specialty Endocrinology Diabetes and Metabolism Urology Blood Pressure Placebo chemistry.chemical_compound Angiotensin Receptor Antagonists Double-Blind Method Internal Medicine medicine Humans Mass Screening Azilsartan Medoxomil Longitudinal Studies Adverse effect Diuretics Mass screening Antihypertensive Agents Creatinine Original Paper Oxadiazoles Dose-Response Relationship Drug business.industry Chlorthalidone Drug Tolerance Middle Aged medicine.disease Original Papers Surgery Blood pressure Treatment Outcome chemistry Hypertension Benzimidazoles Drug Therapy Combination Female Cardiology and Cardiovascular Medicine business Kidney disease medicine.drug Follow-Up Studies
Zdroj:	Journal of Clinical Hypertension (Greenwich, Conn.)
ISSN:	1751-7176 1524-6175
Popis:	A phase 3, 26-week, open-label, titrate-to-target study (n=418) assessed the safety of azilsartan medoxomil (AZL-M) alone and with chlorthalidone (CLD), followed by a 6-week, double-blind, placebo-controlled reversal phase with change in clinic diastolic blood pressure (DBP) as the primary endpoint. Target blood pressure (BP) was
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3aa40b4d137e8d3d250c346af317d339 http://europepmc.org/articles/PMC5024056 Zobrazit plný text záznamu